Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....
Streetwise Reports | October 4, 2019 |

Imagin Medical Poised for Breakout with Bladder Cancer Detection Device in FDA Approval Process

A new advancement in bladder-related endoscopic surgery is endorsed and de-risked. You don't often hear about it, but bladder cancer is the sixth most common cancer in the U.S., with approximately 80,000 cases reported every year, and some 600,000 Americans living in ...
Streetwise Reports | November 13, 2019 |

Disruptive Technology Poised to Deliver Significant Advancement in Bladder Cancer Detection

Chris Temple, editor and publisher of The National Investor, explains why he recommends this small-cap as a Buy. Imagin Medical's disruptive technology is poised to deliver the most significant advancement in bladder cancer detection and removal in decades , ma...
Streetwise Reports | January 15, 2020 |

Biopharma to Test Immunity Activator in Advanced Solid Cancers

The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. In a Dec. 12 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) plans to ...
Streetwise Reports | December 19, 2019 |

Buzz on the Bullboards: The calm before another September rally?

It’s the last leg of what looks like an end-of-month rally as investors try to make the most of August’s losses. Traders are neck-deep into a data-heavy week from company fiscal reports that could chart the hike path for interest rates. ...
Jonathon Brown | August 31, 2023 |

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. Just a few days after reporting third quarter 2019 earnings, late-stage biotechnology company Iovance Biothe...
Streetwise Reports | November 12, 2019 |

Castle Biosciences Shares Storm Higher After Quadrupling Q3 YoY Revenue

Shares of melanoma and other skin cancers diagnostic firm Castle Biosciences Inc. traded more than 15% higher today after the firm announced Q3/19 financial and operational results. Skin cancer diagnostics company Castle Biosciences Inc. (CSTL:NASDAQ) , which provide...
Streetwise Reports | November 13, 2019 |

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced ...
Streetwise Reports | April 21, 2020 |

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody

Curis Inc. shares are up more than 130% and established a new 52-week high price after reporting that the FDA cleared the company's IND Application for CI-8993, its monoclonal anti-VISTA antibody. Biotechnology company Curis Inc. (CRIS:NASDAQ) , which concentrates...
Streetwise Reports | June 11, 2020 |

Buzz on the Bullboards: Do the Dead Cats Bounce?

(Image via CGX Energy Inc.) You’ve heard that what goes up must come down, but in the stock trading world, what goes down should come up. Even a dead cat can bounce if it falls from high enough up, right? The markets coined this term believing th...
Stockhouse Editorial | May 11, 2022 |
1 2 3 4 5